Background: The protein/creatinine (P/C) ratio in urine samples has been used in the clinical management of patients with glomerular diseases. The aim of this study is to perform a prospective evaluation of the P/C ratio accuracy in determining critical levels of proteinuria in patients with glomerulopathies.
Methods: This is a longitudinal study of 41 adult patients with primary glomerulopathies treated with immunosuppressive drugs or angiotensin-converting enzyme inhibitors in a 6-month follow-up. Correlation and agreement level between P24 and the P/C ratio were evaluated. Kappa statistic was employed to evaluate concordance between the two methods taking into account clinically relevant categories of proteinuria. ANOVA for repeated measures was employed. Diagnostic accuracy of the P/C ratio was evaluated by receiver-operator curves (ROC).
Results: There was a significant correlation between P24 and the P/C ratio during the 6-month period (P < 0.001 in all time points). Mean differences between P24 and P/C ratios at baseline and from the first to the sixth month were 2.00, 1.88, 1.22, 1.07, 0.65, 0.34 and 0.57 respectively. In spite of the lower agreement between P24 and the P/C ratio for higher levels of proteinuria, we found substantial Kappa values for categories of proteinuria in all periods. ROC considering the cut-off levels of 0.20 g and 3.5 g for P24 showed that the P/C ratio had a very good accuracy, with areas under the curve of 0.99 (95% CI: 0.97-1.00) and 0.99 (95% CI: 0.99-1.00), respectively.
Conclusion: This longitudinal analysis corroborates the findings of previous cross-sectional studies, supporting the use of the P/C ratio as an accurate test to define critical levels of proteinuria.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ndt/gfm949 | DOI Listing |
Circ Heart Fail
January 2025
Hospital of the University of Pennsylvania, Philadelphia (S.G., J.D.A., B.P., M.J.D., O.S., O.E., P.Z., T.P.C., J.A.C.).
Background: Iron deficiency (ID) is currently defined as a serum ferritin level <100 or 100 to 299 ng/mL with transferrin saturation (TSAT) <20%. Serum ferritin and TSAT are currently used to define absolute and functional ID. However, individual markers of iron metabolism may be more informative than current arbitrary definitions of ID.
View Article and Find Full Text PDFZhejiang Da Xue Xue Bao Yi Xue Ban
January 2025
School of Medicine, Hangzhou City University, Zhejiang Provincial Key Laboratory of Novel Targets and Drug Study for Neural Repair, Hangzhou 310015, China.
Objectives: To investigate the protective effects and underlying mechanisms of extract on motor dysfunction in mouse model of Parkinson's disease (PD).
Methods: Eighty C57BL/6 male mice were randomly divided into five groups: control group, PD model group, levodopa treatment group (positive control group), low-dose GP treatment group (LD-GP group), and high-dose GP treatment group (HD-GP group), with 16 mice per group. The PD model was induced by injection of 6-hydroxydopamine into the substantia nigra pars reticulata in mice of last 5 groups.
J Am Acad Orthop Surg
January 2025
From the Hawaii Permanente Medical Group, Kaiser Permanente, Honolulu, HI (Okike), the Department of Surgical Outcomes and Analysis, Kaiser Permanente, San Diego, CA (Prentice, Paxton, and Fasig), the San Francisco Orthopaedic Residency Program, San Francisco, CA (Shah), the Permanente Medical Group, Oakland, CA (Grimsrud), and the Washington Permanente Medical Group P.C, Seattle, WA (Chen).
Background: Cemented fixation is recommended in the hemiarthroplasty treatment of geriatric femoral neck fractures. Certain cemented stems have similarly designed "low-demand" counterparts, but it is unclear whether they yield comparable clinical outcomes. The purpose of this study was to evaluate the revision risk associated with two low-demand stems, Summit Basic (DePuy Synthes) and Versys LD/Fx (Zimmer Biomet), in comparison to their standard counterparts, Summit (DePuy Synthes) and Versys Advocate (Zimmer Biomet).
View Article and Find Full Text PDFN Engl J Med
January 2025
From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation (C.E.G., E.P.M., N.W., P.R., I.L.W., A.M.B.) and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center (C.E.G., N.W., P.R., A.M.B.) - both in Pittsburgh; AGO-B and Helios Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital, and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), German Breast Group, Neu-Isenburg (P.W., S.L.), and the Center for Hematology and Oncology Bethanien, Goethe University, Frankfurt (S.L.) - all in Germany; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); Orlando Health Cancer Institute, Orlando, FL (E.P.M.); Hospital Universitario La Paz-Instituto de Investigación del Hospital Universitario La Paz, Madrid (A.R.); L'Institut du Cancer de Montpellier-Val d'Aurelle, Montpellier (V.D.), Institut Bergonié, INSERM Unité 1312, and Université de Bordeaux UFR Sciences Médicales, Bordeaux (H.R.B.) - all in France; Providence Cancer Institute, Portland, OR (A.K.C.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and Oncology 2, Istituto Oncologico Veneto IRCCS, Padua (V.G.), and the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (E.R.C.) - all in Italy; Stanford University School of Medicine, Stanford, CA (I.L.W.); the National Cancer Institute, Mexico City (C.A.-S.); Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the All-Ireland Cooperative Oncology Research Group (J.P.C.), and the Oncology Unit, Cancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, and Cancer Trials Ireland (B.T.H.) - all in Dublin; Fudan University Shanghai Cancer Center, Shanghai, China (Z.S.); Institute for Oncology and Radiology of Serbia, Belgrade (L.S.); Grupo Médico Ángeles, Guatemala City, Guatemala (H.C.-S.); Roche Products, Welwyn Garden City, United Kingdom (A.K., A.S.); and F. Hoffmann-La Roche, Basel, Switzerland (C.L., T.B., B.N., E.R.).
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with trastuzumab alone.
Methods: We randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive T-DM1 or trastuzumab for 14 cycles.
Ecotoxicology
January 2025
Unidad Académica Mazatlán, Instituto de Ciencias del Mar y Limnología, Universidad Nacional Autónoma de México, Mazatlán, Sinaloa, México.
Monitoring the dynamics of contaminants in ecosystems helps understand their potential effects. Seabirds have been used as biomonitors of marine ecosystems for this purpose. However, exposure and vulnerability to pollutants are understudied in tropical species, and the relationships between various pollutants and the trophic ecology of seabirds are poorly understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!